Who is sponsoring NCT05344924?

NCT05344924 is sponsored by Zhongda Hospital.

What drugs are being tested in NCT05344924?

Interventions in NCT05344924: TACE+penpulimab+anlotinib vs. penpulimab+anlotinib.

What condition does NCT05344924 study?

NCT05344924 studies Hepatocellular Carcinoma.

Is NCT05344924 still recruiting?

NCT05344924 is currently status unknown. Last updated 29 December 2022.

Last reviewed 2022-12-29 · How we verify

NCT05344924

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TACE Combined With Penpulimab and Anlotinib for Advanced HCC

Status unknown Phase 2, PHASE3 Last updated 29 December 2022

What this trial tests

Phase 2, PHASE3 trial testing TACE+penpulimab+anlotinib vs. penpulimab+anlotinib in Hepatocellular Carcinoma in 109 participants. Status unknown.

Timeline

12 October 2022

Primary endpoint
31 March 2023

31 March 2024

Quick facts

Lead sponsor	Zhongda Hospital
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	109
Start date	12 October 2022
Primary completion	31 March 2023
Estimated completion	31 March 2024
Sites	1 location across China

Drugs / interventions tested

TACE+penpulimab+anlotinib vs. penpulimab+anlotinib — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Zhongda Hospital

Who can join

Adults 18 to 80, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this multicenter, dual-cohort, prospective real-world study is to explore the efficacy and safety of penpulimab and anlotinib combined with or without TACE, as well as the optimum interval of the combination of penpulimab and anlotinib with TACE in advanced HCC patients.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Hepatocellular carcinoma: signaling pathways and therapeutic advances.
Zheng J, Wang S, Xia L, Sun Z, et al · · 2025 · cited 142× · PMID 39915447 · DOI 10.1038/s41392-024-02075-w
Small-molecule-based targeted therapy in liver cancer.
Ming Y, Gong Y, Fu X, Ouyang X, et al · · 2024 · cited 6× · PMID 39113358 · DOI 10.1016/j.ymthe.2024.08.001
How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles.
Fu Y, Zeng CH, An C, Liu Y, et al · · 2023 · cited 5× · PMID 36831664 · DOI 10.3390/cancers15041324
Looking Toward the Future: Emerging Therapies for Hepatocellular Carcinoma.
Rao S, Prince SP, Gaddipati S, Feun L, et al · · 2025 · cited 3× · PMID 40416920
T-cell Receptor Repertoire Analysis in the Context of Transarterial Chemoembolization Synergy with Systemic Therapy for Hepatocellular Carcinoma.
Li J, Zhang Y, Hu L, Ye H, et al · · 2025 · cited 1× · PMID 39801788 · DOI 10.14218/jcth.2024.00238

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Zhongda Hospital trials

Trials by the same sponsor.

NCT07516704 — Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoa · EARLY_PHASE1 · not yet recruiting
NCT07504731 — Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability · recruiting
NCT07351669 — A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepato · recruiting
NCT07311915 — Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in Hi · NA · not yet recruiting
NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05344924 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhongda Hospital
Last refreshed: 29 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05344924.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing